Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan (LNP023) Monotherapy in Complement Inhibitor–Naïve PNH
CTR20211550Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Iptacopan in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Novartis. Started Jul 2021; status: completed.
02
Drugs
Iptacopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on CTR20211550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20211550.